Ertugliflozin is a selective inhibitor of sodium–glucose cotransporter 2 (SGLT2), leading to glucosuria, with HbA1c lowering of 8.3–9.9 mmol/mol (0.8–0.9%) and 2–3 kg of weight loss, and is approved for use as a glucose-lowering therapy in type 2 diabetes mellitus [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.